Cancer therapy deal for Teva and Sinclair

Published: 31 Aug 2011

Teva Pharmaceutical and Sinclair IS Pharma are to team up to promote episil (benzydamine hydrochloride) an oral spray for the treatment of pain in patients undergoing chemotherapy and radiotherapy during cancer treatment.

The licence agreement will see Teva hold exclusive commercialisation rights for episil in Germany, Spain, Poland, Switzerland and the Czech Republic, while Sinclair IS is to retain an option to co-promote the drug in Germany and Spain where it has its own direct sales force.

Financial details of the deal were not disclosed.

Teva said it expects to launch episil in the fourth quarter of 2011.

Chris Spooner, CEO of Sinclair IS, commented that similar agreements were likely for the company in the future. He said: "This is the first in what we expect to be a number of marketing and co-marketing partnerships. episil is a cornerstone of our supportive oncology portfolio and we look forward to working with Teva as we drive sales of this product."

Sinclair IS was formed earlier this year following the merger of Sinclair and IS Pharma.

Published: 31 Aug 2011

Comments are moderated and will not appear until approved by a member of the Communique team.